基于病理学的流感与COVID-19相关肺曲霉病病例系列:组织证据确凿
该单中心回顾性病例系列纳入44例PCR确诊流感或COVID-19呼吸衰竭的ICU死亡患者,经尸检和/或支气管活检组织病理独立复核,确诊6例流感相关和6例COVID-19相关肺曲霉病,组织学均以真菌生长受限为主,支气管肺泡灌洗GM试验敏感性最高。
要点
- 流感与COVID-19重症死亡者中可确诊侵袭性肺曲霉病,组织学模式相似。
- 支气管肺泡灌洗GM试验对病毒相关肺曲霉病诊断敏感性最高。
- 尸检可发现漏诊,但多数为生前 probable 诊断的确认。
核心结论
- 在流感与COVID-19 ICU死亡病例中,确诊侵袭性肺曲霉病常见且组织学模式相似。
- 研究提示需提高对病毒相关肺曲霉病的认识,强调支气管镜真菌学检查。
研究设计与样本
- 单中心、描述性、回顾性病例系列,纳入2009年9月至2021年6月ICU收治的成人PCR确诊流感/COVID-19呼吸衰竭患者,均接受尸检和/或支气管活检。
- 共44例尸检验证队列,由两名经验丰富的病理学家独立复核所有呼吸组织。
主要发现
- 44例尸检队列中确诊6例流感相关和6例COVID-19相关肺曲霉病。
- 确诊病例中8%(n=1/12)为尸检漏诊,52%(n=11/21)为生前 probable 诊断的确认且接受抗真菌治疗。
- 支气管肺泡灌洗GM试验对病毒相关肺曲霉病诊断敏感性最高。
- 两种病毒感染中,真菌生长受限是肺曲霉病主要组织学模式。
- 真菌性气管支气管炎在流感(n=3)与COVID-19(n=3)组织学不可区分,但流感支气管镜下宏观范围更广。
关键数值与推荐
- probable/proven 病毒相关肺曲霉病诊断依据ICU医学流感相关肺曲霉病标准和ECMM/ISHAM COVID-19相关肺曲霉病共识标准。
临床怎么用
- 对重症流感或COVID-19患者应警惕病毒相关肺曲霉病,重视支气管镜真菌学采样。
- 支气管肺泡灌洗GM试验可作为诊断病毒相关肺曲霉病敏感性较高的检测手段。
局限性
- 单中心、描述性、回顾性设计,样本量有限。
- 仅纳入接受尸检和/或支气管活检的ICU死亡患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Invasive pulmonary aspergillosis has emerged as a frequent coinfection in severe coronavirus disease (COVID-19), similarly to influenza, yet the clinical invasiveness is more debated. Objectives: We investigated the invasive nature of pulmonary aspergillosis in histology specimens of influenza and COVID-19 ICU fatalities in a tertiary care center. Methods: In this monocentric, descriptive, retrospective case series, we included adult ICU patients with PCR-proven influenza/COVID-19 respiratory failure who underwent postmortem examination and/or tracheobronchial biopsy during ICU admission from September 2009 until June 2021. Diagnosis of probable/proven viral-associated pulmonary aspergillosis (VAPA) was made based on the Intensive Care Medicine influenza-associated pulmonary aspergillosis and the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM) COVID-19-associated pulmonary aspergillosis consensus criteria. All respiratory tissues were independently reviewed by two experienced pathologists. Measurements and Main Results: In the 44 patients of the autopsy-verified cohort, 6 proven influenza-associated and 6 proven COVID-19-associated pulmonary aspergillosis diagnoses were identified. Fungal disease was identified as a missed diagnosis upon autopsy in 8% of proven cases (n = 1/12), yet it was most frequently found as confirmation of a probable antemortem diagnosis (n = 11/21, 52%) despite receiving antifungal treatment. Bronchoalveolar lavage galactomannan testing showed the highest sensitivity for VAPA diagnosis. Among both viral entities, an impeded fungal growth was the predominant histologic pattern of pulmonary aspergillosis. Fungal tracheobronchitis was histologically indistinguishable in influenza (n = 3) and COVID-19 (n = 3) cases, yet macroscopically more extensive at bronchoscopy in influenza setting. Conclusions: A proven invasive pulmonary aspergillosis diagnosis was found regularly and with a similar histological pattern in influenza and in COVID-19 ICU case fatalities. Our findings highlight an important need for VAPA awareness, with an emphasis on mycological bronchoscopic work-up.
引用
- Vanderbeke L, Jacobs C, Feys S, et al. A Pathology-based Case Series of Influenza- and COVID-19-associated Pulmonary Aspergillosis: The Proof Is in the Tissue. Am J Respir Crit Care Med. 2023. PMID: 37311243. doi:10.1164/rccm.202208-1570OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。